Type B insulin resistance syndrome coexisting with aplastic anemia responsive to early immunosuppressive therapy
Abstract
Type B insulin resistance syndrome (IRS) is a rare autoimmune disorder characterized by severe insulin resistance caused by autoantibodies against the insulin receptor. Clinically, it presents with fluctuating hyperglycemia and hypoglycemia and is frequently associated with other autoimmune diseases. We report a case with the rarely reported combination of type B IRS and aplastic anemia. A 77-year-old woman with obesity presented with abrupt deterioration of glycemic control and bilateral lower extremity edema. Despite the administration of up to 300 units/day of insulin after hospitalization, hyperglycemia remained refractory. Markedly elevated insulin receptor autoantibody titers (85.9%) confirmed the diagnosis of type B IRS. Further evaluation for concomitant pancytopenia revealed aplastic anemia on bone marrow examination. Immunosuppressive therapy with cyclosporine and eltrombopag for aplastic anemia improved the hyperglycemia; however, early morning hypoglycemia, renal dysfunction associated with intravascular volume depletion, and persistent lower extremity edema remained unresolved. The addition of glucocorticoid therapy resulted in rapid clinical improvement and marked reduction in the insulin receptor autoantibody titers (8.6%). This case highlights the importance of early and appropriate immunomodulatory therapy to achieve remission in type B IRS, particularly in patients with multiple concomitant autoimmune diseases.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.